UCB bets $2 billion on Candid's T cell engager ambitions
Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is paying $2 ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] Securing the Untrusted Agentic Development Layer
- [CONFLICT] A responsible choice: Why canceling Lag Ba’omer at Mount Meron was the right call - editorial
- [CONFLICT] 世界卓球で警備員が不適切行為か 台湾女子選手が被害 英で開催
- [CONFLICT] Takaichi Visits Australia to Bolster Ties
- [CONFLICT] FamilyMart stores in Japan start collecting used clothing, goods to reduce waste